InsidersTradesSigma
Follow the 메타바이오메드 stock price and the full management transaction log of the company, a listed equity based in South Korea. Shares trade on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 메타바이오메드 has recorded 4 public disclosures. Market capitalisation: €102.3bn. The latest transaction was filed on 27 April 2026 (Purchase). Among the most active insiders: 오지수. Every trade is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
4 of 4 declarations
Meta Biomed is a company listed on the XKRX market, specializing in the healthcare and pharmaceutical sector. It focuses on the development and commercialization of innovative solutions for the medical field.